jueves, 22 de octubre de 2015

WHO Pharmaceuticals Newsletter No. 5, 2015



OMS, 22 de octubre de 2015

Tabla de contenidos

Regulatory Matters
  • Amantadine hydrochloride
  • Asunaprevir and daclatasvir
  • Azithromycin hydrate
  • Canagliflozin
  • Clozapine
  • Deferasirox
  • Fingolimod
  • Hydroxyzine-containing medicines
  • Infliximab
  • Ingenol mebutate gel
  • Laninamivir octanoate and zanamivir
  • Memantine hydrochloride
  • Nivolumab
  • Panitumumab
  • Pomalidomide
  • Proton pump inhibitors
  • Risperidone
  • Sodium-glucose co-transporter 2 (SGLT2) inhibitors
  • Sterile talc
  • Treanda® Injection


Safety of medicines
  • Bortezomib
  • Brintellix® (vortioxetine) and Brilinta® (ticagrelor)
  • DPP-4 Inhibitors for Type 2 Diabetes
  • Eltrombopag
  • Etanercept
  • Gadolinium-based Contrast Agents for Magnetic Resonance Imaging (MRI)
  • Pseudoephedrine and ephedrine
  • Rivaroxaban
  • Tramadol oral drops

Signal
  • Dextromethorphan and serious neurological disorders in children
  • Olanzapine and accidental drug intake by children
  • Temozolomide and Oesophagitis

Feature
  • WHO-UMC-HSA Inter-Regional Pharmacovigilance Training, Singapore, 30 September -2 October
  • 2015
  • The World Health Organization organizes an integrated vigilance workshop for Eastern Mediterranean regional countries in Rabat
  • Building Pharmacovigilance in Member States of Central African Economic Monetary Community (CEMAC)

Disponible en http://bit.ly/1RYJ2M2